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A novel interaction between CX3CR1 and
CCR2 signalling in monocytes constitutes
an underlying mechanism for persistent
vincristine-induced pain
Karli Montague1* , Raffaele Simeoli1,2, Joao Valente3 and Marzia Malcangio1*
Abstract
Background: A dose-limiting side effect of chemotherapeutic agents such as vincristine (VCR) is neuropathic pain,
which is poorly managed at present. Chemokine-mediated immune cell/neuron communication in preclinical
VCR-induced pain forms an intriguing basis for the development of analgesics. In a murine VCR model, CX3CR1
receptor-mediated signalling in monocytes/macrophages in the sciatic nerve orchestrates the development of
mechanical hypersensitivity (allodynia). CX3CR1-deficient mice however still develop allodynia, albeit delayed; thus,
additional underlying mechanisms emerge as VCR accumulates. Whilst both patrolling and inflammatory monocytes
express CX3CR1, only inflammatory monocytes express CCR2 receptors. We therefore assessed the role of CCR2 in
monocytes in later stages of VCR-induced allodynia.
Methods: Mechanically evoked hypersensitivity was assessed in VCR-treated CCR2- or CX3CR1-deficient mice.
In CX3CR1-deficient mice, the CCR2 antagonist, RS-102895, was also administered. Immunohistochemistry and
Western blot analysis were employed to determine monocyte/macrophage infiltration into the sciatic nerve as
well as neuronal activation in lumbar DRG, whilst flow cytometry was used to characterise monocytes in
CX3CR1-deficient mice. In addition, THP-1 cells were used to assess CX3CR1-CCR2 receptor interactions in vitro,
with Western blot analysis and ELISA being used to assess expression of CCR2 and proinflammatory cytokines.
Results: We show that CCR2 signalling plays a mechanistic role in allodynia that develops in CX3CR1-deficient
mice with increasing VCR exposure. Indeed, the CCR2 antagonist, RS-102895, proves ineffective in mice
possessing functional CX3CR1 receptors but reduces VCR-induced allodynia in CX3CR1-deficient mice, in which
CCR2
+ monocytes are elevated by VCR. We suggest that a novel interaction between CX3CR1 and CCR2 receptors
in monocytes accounts for the therapeutic effect of RS-102895 in CX3CR1-deficient mice. Indeed, we observe
that CCR2, along with its ligand, CCL2, is elevated in the sciatic nerve in CX3CR1-deficient mice, whilst in THP-1
cells (human monocytes), downregulating CX3CR1 upregulates CCR2 expression via p38 MAP kinase signalling.
We also show that the CX3CR1-CCR2 interaction in vitro regulates the release of pronociceptive cytokines TNF-α
and IL1β.
Conclusions: Our data suggests that CCL2/CCR2 signalling plays a crucial role in VCR-induced allodynia in
CX3CR1-deficient mice, which arises as a result of an interaction between CX3CR1 and CCR2 in monocytes.
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Background
Chemotherapy-induced painful neuropathy (CIPN) is
a dose-limiting side effect of chemotherapeutic drugs,
which is poorly managed by analgesics at present [1].
Current treatments for CIPN such as gabapentin and
opioids show limited efficacy and engender a host of
undesirable side effects such as dizziness and nausea
[2, 3]. Indeed, it has been reported that in as many
as 40% of patients [4], CIPN results in the premature
cessation of chemotherapy and thus jeopardises can-
cer treatment success. It is therefore essential that
novel, more efficacious analgesics are developed and
tailored according to different chemotherapeutic
agents, which have a broad range of actions. This
warrants a deeper understanding of the underlying
drug-specific mechanisms of CIPN.
Most chemotherapeutic agents do not cross the
blood-brain barrier but are able to penetrate the
blood-nerve barrier, where they accumulate in dorsal
root ganglia (DRG) and peripheral nerves, causing
toxicity that is intensified by the absence of a lymph-
atic system in the endoneurial compartment [5–7].
Treatments that are currently used for CIPN are predom-
inantly ‘neurocentric’ therapies, which target neuronal re-
sponses to injury inflicted by chemotherapeutic agents.
Compelling evidence from preclinical models of CIPN in
recent years however has uncovered the importance of
immune cells, such as monocytes/macrophages, and their
communication at the endothelial-neuronal interface
peripherally [8, 9].
One chemotherapeutic agent associated with
neuropathic pain is the vinca alkaloid, vincristine
(VCR), used most commonly in the treatment of
lymphomas and leukaemias [10]. In a preclinical
model of VCR-induced pain, VCR-mediated activa-
tion of the endothelium promotes the infiltration of
CX3CR1-expressing monocytes into peripheral nerves,
where they differentiate into macrophages and acti-
vate TRPA1 channels on sensory neurons via the re-
lease of reactive oxygen species [9]. An increase in
monocyte infiltration into the sciatic nerve is causa-
tive of mechanical hypersensitivity (allodynia), as
opposed to being an epiphenomenon or downstream
event, on the basis that transient depletion of macro-
phages delays the onset of allodynia until such
depletion is ceased and macrophages can populate
the sciatic nerve [9]. Communication between monocytes/
macrophages and sensory neurons in the periphery has
been found to be a key underlying mechanism in preclin-
ical CIPN associated with other chemotherapeutic agents
such as paclitaxel. Indeed, depletion of macrophages in
the DRG prevents paclitaxel-induced allodynia [11, 12].
Furthermore, inhibition of CX3CR1-mediated activation
of macrophages specifically, as well as inhibition of
p38 MAPK, a downstream target of CX3CR1 activation,
also blocks the development of paclitaxel-induced allo-
dynia [11].
Despite the promise of targeting CX3CR1 receptors in
monocytes/macrophages as a prophylaxis for VCR pain,
and, indeed, pain associated with other chemotherapeu-
tic agents, a critical caveat remains: CX3CR1-deficient
mice still develop VCR-induced allodynia, albeit delayed
[9]. It therefore appears that the role of CX3CR1 in
monocytes is dynamic and alternative mechanisms
emerge with increased exposure to VCR. In this study,
we attempt to elucidate such a mechanism that could
account for the eventual onset of VCR-induced allodynia
in CX3CR1-deficient mice.
Circulating monocytes can, very broadly speaking,
exist as two phenotypes—‘patrolling’ or ‘inflamma-
tory’, each of which expresses distinct markers [13].
Patrolling monocytes, characterised by low expression
of Ly6C (Ly6Clow) and high levels of CX3CR1
(CX3CR1
high), are predominantly associated with
homeostatic functions [14]. Inflammatory or ‘classical’
monocytes however express high levels of Ly6C
(Ly6Chigh) and relatively low levels of CX3CR1
(CX3CR1
low). Unlike patrolling monocytes, inflamma-
tory monocytes express the chemokine receptor
CCR2 (CCR2
+). In the sciatic nerve, CCR2 receptor is
activated by CCL2, which is expressed by endothelial
cells, monocytes/macrophages and sensory neurons
[15–17]. Inflammatory monocytes are recruited to
sites of injury and inflammation in a CCL2/CCR2-
regulated fashion, releasing a multitude of factors,
many of which exert pronociceptive functions [18]. It
is well-established that neuronal injury, such as that
caused by chemotherapy, is accompanied by an in-
crease in macrophages with the inflammatory CCR2
+
phenotype [19, 20].
In this study, we therefore investigate the role of
CCL2/CCR2 signalling in inflammatory monocytes/
macrophages in VCR-induced allodynia—specifically
at later stages of treatment, when the role of CX3CR1
is less pertinent. Given that the CCR2 receptor is also
expressed in sensory neurons [17], we also consider
the role of CCR2-mediated neuronal activation in
order to differentiate between the roles of CCR2 sig-
nalling in sensory neurons and monocytes. As well as
attempting to elucidate the role of CCR2
+ monocytes/
macrophages in VCR-induced allodynia in CX3CR1-de-
ficient mice, we also investigate a potential interaction
between CX3CR1 and CCR2 expression in immortalised
human monocytes (THP-1 cells). Furthermore, we as-
sess the regulation of pronociceptive cytokines from
THP-1 cell downstream of the CX3CR1-CCR2 interaction,
which could constitute a potential monocyte-derived
signal that mediates monocyte communication with
Montague et al. Journal of Neuroinflammation  (2018) 15:101 Page 2 of 15
nociceptive neurons, which are known to express cytokine
receptors [21].
Methods
Animals
Experiments were performed in accordance with the
United Kingdom Animals (Scientific Procedures) Act 1986
and local animal care and use guidelines. Male and female
mice (25–30 g, 12–17 weeks of age) were used. They did
not differ with respect to thresholds. Mice were randomly
assigned to groups. Each group contained approximately
equal numbers of age-matched mice of both sexes.
For Cx3cr1-gfp (green fluorescent protein) mice, an
original breeding stock was a kind gift from Steffen Jung
(Weizmann Institute of Science, Israel). Cx3cr1-gfp het-
erozygous mice were generated and genotyped as de-
scribed [9]. For Ccr2-rfp (red fluorescent protein) mice,
an original breeding stock was purchased from Jackson
Laboratory. Ccr2 disruption/RFP expression was con-
firmed by PCR using published primers [22]. All mice
used were generated from a C57Bl/6 background.
Behavioural testing
Static mechanical withdrawal thresholds were assessed
as described previously [9]. Briefly, unrestrained animals
were acclimatised for 45 min prior to testing. Calibrated
von Frey filaments (0.008–1.4 g) were applied to the
plantar surface of the hind paw until they bent and were
held for 3 s or until paw withdrawal. A 50% paw with-
drawal threshold (in grams) was calculated using the
‘up-down’ method starting with the 0.6-g filament. Three
baseline (B) measurements were made prior to treat-
ment, the mean of which is presented. Bilateral measure-
ments were made with no difference in threshold being
recorded between left and right (data not shown). Data
presented are means of the left and right hind paw
thresholds. All tests were conducted blind.
Drug administration
Vincristine sulphate (VCR; Sigma-Aldrich) was dissolved
in sterile saline. 0.5 mg/kg/day VCR was injected intraper-
itoneally (i.p.) using a 25-g needle for two 5-day cycles
(days 0–4 and 7–11) with a 2-day break as previously de-
scribed [9]). RS-102895 hydrochloride (Sigma), which is
small molecule antagonist of CCR2 receptor belonging to
the spiro-piperidine class, was dissolved in dimethyl
sulphoxide (DMSO) at 10 mg/ml and diluted in sterile sa-
line; 20 mg/kg/day was injected i.p. for 5 days [23] during
the second VCR cycle.
Immunohistochemistry
Mice, under pentobarbital anaesthesia, were transcardially
perfused with saline, followed by 4% paraformaldehyde
(PFA). The lumbar enlargement, bilateral L3–5 DRG, and
sciatic nerves were excised. Tissue was post-fixed for 4 h
and then dehydrated in 30% sucrose in PBS before being
embedded in optimum cutting temperature-embedding
medium (VWR) and frozen on dry ice. Fifteen-micrometer
cryosections were mounted onto Superfrost Plus slides
(VWR). Sections were permeabilised for 15 min at room
temperature in 0.1% PBS-Triton X-100 (Sigma-Aldrich).
Slides were blocked in 0.1% PBS-Triton X-100 + 3% BSA
(Sigma-Aldrich) for 1 h at room temperature before being
incubated in primary antibody at 4 °C for 16 h. Slides were
washed thrice in 0.1% PBS-Triton X-100, before being incu-
bated with the appropriate fluorescently tagged secondary
antibody for 1.5 h at room temperature. Slides were washed
again and then mounted using FluorSave™ (Merck, UK)
and visualised under a Zeiss LSM710 confocal microscope
(Zeiss). Five sections per mouse were randomly selected
and analysed blind as described previously [9].
Antibodies
To visualise microglia, anti-Iba1 (1:100, WAKO) and
anti-rabbit Alexa Fluor 488 (1:1000, Invitrogen) were
used. For F4/80 expression, anti-F4/80 (1:400, Abcam)
was used followed by anti-rat Alexa 488 or 568 (both
1:1000, Invitrogen). For CCL2 in the sciatic nerve, anti-
CCL2 (1:200, Invitrogen) and anti-rabbit Alexa 568
(1:1000, Invitrogen) were used. P-ERK visualisation in
DRG was carried out using anti-p-ERK (1:300, Cell
Signaling Technology) followed by anti-rabbit Alexa 568
(1 in 1000 Invitrogen). GFP did not require amplifica-
tion. In all cases, control staining was performed in
which no primary antibody was applied.
Western blot
Sciatic nerves were fresh-dissected, snap-frozen and stored
at − 80 °C. Tissue was homogenised in ice-cold RIPA buffer
(20 mM tris(hydroxymethyl)aminomethane; 10 mM NaF;
150 mM NaCl; 1% nonyl-phenoxylpolyethoxylethanol;
1 mM phenylmethanesulfonyl fluoride; 1 mM Na3VO4
(all Sigma-Aldrich); and 10 mg/ml proteinase inhibitor
(Roche)) before being incubated at 4 °C with agitation
for 2 h. Samples were centrifuged at 4 °C and
13,000 rpm for 20 min. Supernatant was used for Western
blot. For THP-1 cultures, medium was spun at 2000g for
5 min at 4 °C. The pellet was washed, re-suspended in
radioimmunoprecipitation assay (RIPA) buffer, vortexed
and kept on ice for 30 min, and then spun at 13,000 rpm
at 4 °C for 10 min. The supernatant was collected. Protein
concentration was determined using the bicinchoninic
acid (BCA) protein assay (Pierce). Twenty micrograms of
protein per sample was separated on a 15% SDS-PAGE
gel and transferred onto a nitrocellulose membrane which
was performed according to the manufacturer’s instruc-
tions (Bio-Rad, UK). Blots were blocked for 1 h at room
temperature in 0.1% TBS-Tween-20 (TBST) + 5%
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skimmed milk before being incubated in primary anti-
body (F4/80), CCL2 (anti-mouse or human), CCR2
(anti-mouse or human) (all 1:1000, Abcam) and p-ERK
(1:1000 Cell Signaling Technology) at 4 °C overnight along
with a loading control (α-tubulin, β-actin both 1:1000,
Abcam). After washing in 0.1% TBST, blots were incu-
bated for 1 h at room temperature with HRP-conjugated
secondary antibody (1:2000, DAKO). Blots were washed
before being developed with SuperSignal™ West Femto
substrate (Thermo Fisher Scientific). Bands were visua-
lised using BioSpectrum© Imaging and quantified using
Quantity One (Bio-Rad, UK).
Flow cytometry
Mice were sacrificed by a rising concentration of CO2.
Peritoneal cells were then elicited by injecting saline into
the peritoneal cavity. Lavages were collected and centri-
fuged at 2400 rpm for 10 min. Pellets were suspended in
red phenol-free DMEM (Gibco) supplemented with 10%
heat-inactivated foetal bovine serum (HI-FBS), 1% pen/
strep and 1% sodium pyruvate. Cells were incubated
with conjugated antibodies (CD45.1-Pacific Blue (BioLe-
gend); F4/80-PE (eBioscience); Alexa Fluor® 647 anti-
mouse CD192 (CCR2) Antibody (BioLegend); Ly-6C
APC (eBioscience)) on ice for 30 min and then washed
twice with PBS containing 1.5% BSA before being re-
suspended prior to analysis. Cells were gated and ana-
lysed with LSRFortessa™ (BD bioscience) and FlowJo
software (Tree Start).
THP-1 culture
THP-1 cells were a kind gift from Mauro Perretti
(Queen Mary, University of London). Cells were cul-
tured in RPMI 1640 with 10% FBS and 2 mM glutamine
(Sigma-Aldrich) and maintained in upright T25 tissue
culture flasks. For all experiments, cells were cultured in
24-well plates. Cells were transfected using Lipofectamine
RNAiMAX (Thermo Fisher Scientific) with CX3CR1 siRNA
(Insight Biotechnology) or control SignalSilence®siRNA
(New England Biolabs) 24 h after seeding, and assays were
performed 48 h post-transfection. Efficiency of CX3CR1
knockdown was determined using Western blot. In some
experiments, cells were pre-treated, 1 h before transfection
with siRNA, with SB203580 or PD98059 (both 25 μM,
Cambridge Bioscience). For CCL2 stimulation, cells were
treated for 3 h with human recombinant CCL2 (Cambridge
Bioscience) at 10, 50 and 100 ng/ml in HEPES buffer.
Cytokine/chemokine measurement
CCR2 expression was measured using human chemokine
C-C-motif receptor 2 (CCR2) ELISA Kit (2B Scientific) ac-
cording to the manufacturer’s instructions. For cytokine
expression, a multi-analyte ELISA for proinflammatory cy-
tokines (Qiagen) was performed on culture medium to
assess which cytokines were upregulated. ELISA was then
performed specifically for TNFα and IL1β (Abcam) ac-
cording to the manufacturer’s instructions.
Statistics
All data were analysed using SPSS (IBM Analytics). Be-
havioural data were analysed by repeated measures (RM)
two-way ANOVA, followed by Tukey’s test. All other in
vivo data were analysed by one-way ANOVA, followed by
Tukey’s test. All in vitro data was analysed using Student’s
paired t test. All data are shown as mean ± SEM, and data
were considered significant when p < 0.05.
Results
CCR2-deficient mice develop reduced allodynia relative to
CCR2 heterozygous controls at higher cumulative doses
of vincristine
In order to establish whether CCR2 receptor signalling
plays a role in VCR-induced allodynia, CCR2-deficient
mice (CCR2
RFP/RFP) were treated with two 5-day cycles of
VCR [9, 24]. In the first cycle, they were found to de-
velop significant VCR-induced allodynia to the same se-
verity and within the same time frame as heterozygous
(CCR2
+/RFP), littermate controls (Fig. 1a). Specifically,
within 24 h of the first VCR dose and throughout the
first treatment cycle, mechanical withdrawal thresholds
of both CCR2-deficient and heterozygous mice were
significantly reduced relative to saline-treated mice. In-
deed, there was no difference in threshold between
VCR-treated CCR2-deficient and heterozygous mice
throughout the first VCR cycle (days 0–4). During the
second cycle of VCR however, CCR2-deficient mice had
significantly higher thresholds, thus reduced allodynia,
relative to heterozygous controls (Fig. 1a).
VCR-induced monocyte infiltration in peripheral nerve
tissue is significantly reduced in CCR2-deficient mice
during the second VCR cycle
We initially confirmed that VCR administration did not
cause a measurable microglial response (Additional file 1:
Figure S1A, B), before focussing our attention on the
sciatic nerve, where VCR accumulates and mechanisms
underlying preclinical VCR pain are most pertinent [9].
In CCR2 heterozygous mice, the elevation of macro-
phages in the sciatic nerve occurred to the same degree
during both the first and second cycles of VCR treatment
as demonstrated by immunohistochemical (Fig. 1b, c) and
Western blot detection (Fig. 1d, e) of the macrophage
marker F4/80. In CCR2-deficient mice however, when
allodynia was significantly reduced during the second
cycle relative to the first cycle, we observed that F4/80 ex-
pression was also significantly reduced in the sciatic nerve
relative to the first VCR cycle (Fig. 1b–e).
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Treatment of CX3CR1 heterozygous mice with a CCR2
antagonist does not reduce VCR-induced allodynia or
monocyte infiltration in the sciatic nerve
In light of the apparent involvement of the CCR2 recep-
tor in VCR allodynia during the second VCR cycle, we
wanted to establish if treatment with a CCR2 antagonist
on VCR-induced allodynia mirrors genetic deficiency, as
well as identify whether CCR2 does indeed play a role in
VCR-induced allodynia in CX3CR1-deficient mice during
the second cycle. To address the first of these questions,
we began by administering the CCR2 antagonist RS-
102895 during the second VCR cycle to CX3CR1
a
b c
d e
Fig. 1 CCR2-deficient mice have reduced VCR allodynia and monocyte infiltration in the sciatic nerve during the second cycle. a Mechanical
thresholds are significantly higher in VCR-treated CCR2-deficient (RFP/RFP) mice than heterozygous controls during the second cycle (days 8–11).
Data expressed as 50% paw withdrawal thresholds (mean ± SEM, n = 8 mice per group). *p < 0.05 and **p < 0.01 compared to time-matched
VCR-treated CCR2
+/RFP thresholds, two-way RM ANOVA, post hoc Tukey’s test. b Representative images showing macrophages (F4/80, green) in
longitudinal sections of sciatic nerves of CCR2
+/RFP and CCR2
RFP/RFP mice during both VCR cycles. Scale bar = 200 μm. c Quantification of F4/80
immunoreactive (+) profiles per 104 μm2 (mean ± SEM, n = 4 mice per group; five fields of view were quantified for each mouse). There is a
significant reduction in F4/80+ profiles in CCR2
RFP/RFP sciatic nerves in cycle 2, relative to CCR2
RFP/RFP sciatic nerves during cycle 1 and relative to
CCR2+/RFP during cycle 2. *p < 0.05, one-way ANOVA, Tukey’s test. d Representative blot of F4/80 (130 kDa) and α-tubulin loading control
(50 kDa) in sciatic nerve homogenates obtained from CCR2
+/RFP and CCR2RFP/RFP mice during VCR cycles 1 and 2. e Quantification of F4/80
band density normalised to α-tubulin (mean ± SEM, n = 3). F4/80 expression is unchanged in CCR2+/RFP sciatic nerve homogenates between
VCR cycles 1 and 2. In CCR2
RFP/RFP sciatic nerve homogenates, there is a significant reduction in normalised F4/80 expression in cycle 2 (day 11)
relative to cycle 1 (day 4). *p < 0.05, one-way ANOVA, Tukey’s test
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heterozygous mice, which possess functional CX3CR1.
Our rationale for therapeutic (VCR cycle 2) as opposed
to prophylactic (VCR cycle 1) dosing was derived not
only from the apparent effect of CCR2 deficiency on
VCR-induced allodynia during the second VCR cycle
specifically but also from previous observations that
whilst the development of VCR-induced allodynia is or-
chestrated by CX3CR1 signalling in monocytes, other
mechanisms appear to regulate allodynia during the sec-
ond VCR cycle [9]. Indeed, prophylactic treatment with
RS-102895 during the first VCR cycle had no effect on
withdrawal thresholds (Additional file 1: Figure S2).
However, we found that when CX3CR1 heterozygous
mice were given RS-102895 during the second VCR
cycle, there was still no change in VCR-induced allody-
nia (Additional file 1: Figure S3A). Concurrently,
VCR-induced monocyte/macrophage infiltration into
the sciatic nerve was also unaltered by administration
of RS-102895 during the second VCR cycle (Add-
itional file 1: Figure S3B, C).
Treatment of CX3CR1-deficient mice with a CCR2
antagonist significantly reduces VCR-induced allodynia
and monocyte infiltration into peripheral nervous tissue
Although our data so far suggests that CCR2 antagonism
during the second VCR cycle is not necessarily thera-
peutic in mice possessing functional CX3CR1 receptor,
this does not rule out a role for CCR2-mediated signal-
ling in VCR-induced allodynia that has been observed
in CX3CR1-deficient mice at later stages of treatment [9].
We therefore treated CX3CR1-deficient (CX3CR1
GFP/GFP)
mice with two cycles of VCR in the presence of RS-
102895 (or vehicle) during the second VCR cycle, when
allodynia manifests in CX3CR1-deficient mice [9]. As ob-
served previously, CX3CR1-deficient mice displayed a de-
layed onset of allodynia in response to VCR treatment
relative to heterozygous littermates. Whilst CX3CR1 het-
erozygous mice developed significant allodynia within
24 h of the first VCR dose (Additional file 1: Figure S3A),
mechanical thresholds only dropped significantly in
CX3CR1-deficient mice relative to saline-treated con-
trols at the end of the first VCR cycle (Fig. 2a). In
addition, dissimilar to the results obtained in CX3CR1
heterozygous mice, systemic treatment of CX3CR1-de-
ficient mice with RS-102895 during the second VCR
cycle significantly reduced VCR-induced allodynia
(Fig. 2a). Although withdrawal thresholds in CX3CR1-
deficient mice treated with RS-102895 alongside VCR
were still significantly lower than baseline levels, a
significant increase relative to CX3CR1-deficient mice
treated with VCR alone was observed within 24 h of
the first RS-102895 dose and persisted throughout the
second VCR cycle. Crucially, administration of RS-
102895 in all saline-treated mice did not alter
mechanical thresholds (Fig. 2a, Additional file 1: Figure S3).
This data exposes a potential role for CCL2/R2 signalling in
VCR-induced allodynia in CX3CR1-deficient mice during
the second cycle specifically.
Given that RS-102895 significantly reduced VCR-
induced allodynia in CX3CR1-deficient mice during the
second VCR cycle, we assessed whether it also resulted
in a simultaneous reduction in VCR-induced monocyte
infiltration into the sciatic nerve. In CX3CR1 heterozygous
mice, RS-102985 administration during the second VCR
cycle did not significantly reduce VCR-induced monocyte
infiltration into the sciatic nerve, as demonstrated by im-
munohistochemistry (Fig. 2b, c) and Western blot analysis
(Fig. 2d, e) of F4/80. However, the administration of RS-
102895 to VCR-treated CX3CR1-deficient mice did indeed
result in a significant reduction in macrophage number in
the sciatic nerve (Fig. 2b–e). This suggests that the mech-
anism by which RS-102895 significantly reduces VCR-
induced allodynia in CX3CR1-deficient mice is, at least in
part, regulated by CCR2 signalling in, or CCR2-mediated
recruitment of, monocytes/macrophages in peripheral
nerves. Furthermore, the reduction in VCR-induced allo-
dynia and monocyte infiltration that accompanied the ad-
ministration of RS-102895 to CX3CR1-deficient mice
specifically is suggestive of changes in CCR2 expression
and/or activity as a result of loss of CX3CR1 in mono-
cytes/macrophages in the periphery.
The reduction in VCR-induced allodynia in CX3CR1-deficient
mice treated with RS-102895 does not require sensory
neuron CCR2 receptors
Unlike CX3CR1, which is predominantly expressed by
monocytes/macrophages, CCR2 is additionally expressed
on sensory neurons [16, 17]. To investigate the potential
contribution of CCR2 signalling in sensory neurons to
the reduction in VCR-induced allodynia observed in RS-
102895-treated CX3CR1-deficient mice, we considered
the effect of RS-102895 on CCR2-mediated neuronal ac-
tivation. In both CX3CR1-deficient and heterozygous
mice, two cycles of VCR administration resulted in the
upregulation of phospho-p44/42 MAPK2 (p-ERK2), a
marker for neuronal activation and downstream target
of CCR2 signalling [25, 26] as demonstrated by both im-
munohistochemistry (Fig. 3a, b) and Western blot
analysis in lumbar DRG (Fig. 3c, d). Administration of
RS-102895 for the duration of the second VCR cycle
however resulted in a significant reduction of p-ERK2 in
lumbar DRG from both CX3CR1-deficient and heterozy-
gous mice (Fig. 3a–d) suggesting that the effect of RS-
102895 on VCR-induced elevation of p-ERK2 did not
differ between genotypes. Crucially, at day 14 (3 days
after treatment cessation), VCR-treated CX3CR1-deficient
mice that had received RS-102895 still had significantly
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Fig. 2 RS-102895 significantly reduces VCR-induced allodynia and monocyte infiltration in the sciatic nerve in CX3CR1-deficient mice. a CX3CR1
knockout (GFP/GFP) mice were treated with two VCR cycles alongside the CCR2 antagonist RS-102985, or vehicle, during the VCR cycle 2.
CX3CR1
GFP/GFP mice developed VCR-induced allodynia at the end of cycle 1 (day 4) as previously reported. Data expressed as 50% paw withdrawal
thresholds (mean ± SEM, n = 6–9 mice per group). In VCR/RS-102895-treated CX3CR1
GFP/GFP mice (red trace), withdrawal thresholds increased
significantly relative to VCR/vehicle-treated CX3CR1
GFP/GFP mice (blue) within 24 h of the first antagonist dose. *p < 0.05, two-way RM ANOVA,
Tukey’s test. b Representative images of macrophages (F4/80, red) in sciatic nerve longitudinal sections at day 11 from VCR-treated CX3CR1
GFP/GFP and
CX3CR1
+/GFP mice. Scale bar = 50 μm. c Quantification of F4/80+ profiles per 104 μm2 in the sciatic nerve at day 11 (mean ± SEM, n = 4 mice per group;
five fields of view were quantified for each mouse). RS-102985 significantly reduces VCR-induced elevation of F4/80+ profiles in sciatic nerves from
CX3CR1
GFP/GFP mice. NS not significant, **p < 0.01, one-way ANOVA, Tukey’s test. d Representative blot of F4/80 (130 kDa) and α-tubulin (50 kDa) in
sciatic nerve homogenates obtained from CX3CR1
+/GFP and CX3CR1
GFP/GFP mice at day 11. e Quantification of F4/80 band density normalised to α-tubulin
(mean ± SEM, n= 3). RS-102985 significantly reduces VCR-associated infiltration into sciatic nerves obtained from CX3CR1
GFP/GFP mice. NS not significant,
*p< 0.05, one-way ANOVA, post hoc Tukey’s test
Montague et al. Journal of Neuroinflammation  (2018) 15:101 Page 7 of 15
a b
e f
g h
c d
Fig. 3 Reduction in VCR-induced allodynia by RS-102985 does not require neuronal activation. a Representative images of GFP (macrophages,
CX3CR1, green) and p-ERK (neuronal activation, red) in L4 DRG taken from VCR-treated CX3CR1
+/GFP and CX3CR1
GFP/GFP mice at treatment day 11.
Mice were co-treated with RS-102985 or vehicle. Scale bar, 50 μm. b Quantification of p-ERK+ profiles per mm2 at day 11 (mean ± SEM, n = 4 mice
per group). VCR induces neuronal activation, which is significantly reduced by RS-102895 at day 11. ***p < 0.001, one-way ANOVA, Tukey’s test.
c Representative blot of p-ERK2 (42 kDa) and α-tubulin (50 kDa) in L3–L5 DRG homogenates obtained from CX3CR1+/GFP and CX3CR1GFP/GFP mice at
treatment day 11. d Quantification of p-ERK2 band density normalised to α-tubulin (mean ± SEM, n = 3). In both genotypes, RS-102895 administration
significantly reduces VCR-induced p-ERK2 expression in L3–L5 DRG. *p < 0.05, one-way ANOVA, Tukey’s test. e Withdrawal thresholds at days 14–16
remain significantly higher in VCR/RS-102895-treated CX3CR1
GFP/GFP mice relative to those treated with VCR and vehicle (mean ± SEM, n = 6–9 mice per
group). *p < 0.05, two-way RM ANOVA, Tukey’s test. f Representative images of GFP (macrophages) and p-ERK (red) in L4 DRG taken from CX3CR1
+/GFP
and CX3CR1
GFP/GFP mice at day 14. Prior RS-102895 treatment does not continue to prevent p-ERK activation in either genotype. Scale bar = 50 μm.
g Quantification of p-ERK+ profiles per mm2 at day 14 (mean ± SEM, n = 4 mice per group). NS not significant. h Representative blot and quantification
of p-ERK2 and α-tubulin in bilateral L3–L5 DRG homogenates. In both genotypes, DRG from VCR/RS-102895-treated mice express similar normalised
p-ERK2 expression to VCR/vehicle-treated mice (mean ± SEM, n = 3)
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reduced allodynia relative to CX3CR1 heterozygous mice
(Fig. 3e). However, p-ERK2 activation was observed in
lumbar DRG at this time point regardless of genotype, as
demonstrated by immunohistochemistry (Fig. 3f, g) and
Western blot analysis (Fig. 3h). This could suggest that
the reduction in VCR-associated allodynia in RS-102895-
treated CX3CR1-deficient mice is not entirely dependent
on the diminution of sensory neuronal activation via
CCR2 receptor antagonism and could therefore also be
regulated by CCR2 signalling elsewhere, such as that
present in monocytes/macrophages.
This data also indicates that it is less likely that the
absence of effect of RS-102895 in CX3CR1 heterozygous
mice was due to lack of bioavailability. Activation of p-
ERK is a well-established downstream event of CCR2
receptor activation; thus, the fact that VCR-induced p-
ERK activation was only reduced when RS-102895 was
administered and not at day 14, at which point treat-
ment was terminated (Fig. 3e–g), provides us with a
measureable outcome of RS-102895 bioavailability and
target engagement.
CCL2/R2 expression is altered in macrophages in the
sciatic nerve of CX3CR1-deficient mice
Given the effect of RS-102895 treatment on CX3CR1-
deficient mice specifically and that CX3CR1 deficiency
is associated with CCL2 upregulation in phagocytic cells
[27, 28], we went on to examine CCL2 expression in
the sciatic nerve of CX3CR1-deficient mice. Western
blot analysis of CCL2 expression in sciatic nerve ho-
mogenates from CX3CR1-deficient and heterozygous
mice that had been treated with saline only demon-
strated that CCL2 elevation in the sciatic nerve accom-
panied CX3CR1 deficiency (Fig. 4a, b). In addition, we
found that two VCR cycles increased CCL2 expression
in the sciatic nerve of both CX3CR1-deficient and het-
erozygous mice (Fig. 4a, b). Immunohistochemical ana-
lysis of GFP+ (macrophages) and CCL2+ profiles in the
sciatic nerve suggested that increases in CCL2 in the
sciatic nerve in CX3CR1-deficient mice and in both ge-
notypes in response to VCR treatment were, at least in
part, a result of an increase of CCL2 in macrophages
(Fig. 4c, d). In order to confirm that the results ob-
tained were not a misrepresentation afforded by poten-
tial antibody artifacts, we confirmed that CCL2 could
not be detected in sciatic nerve tissue from CCL2-defi-
cient mice (data not shown).
CX3CR1 deficiency is associated with high CCR2
+ monocyte
infiltration in peripheral nerves
Our data to this point demonstrates that (i) treatment
with a CCR2 antagonist (RS-102895) reduces VCR-
induced allodynia and monocyte/macrophage infiltration
in sciatic nerves in CX3CR1-deficient mice during cycle
two specifically and (ii) VCR induces CCL2 elevation in
monocytes/macrophages. However, whether VCR allody-
nia is associated with peripheral nerve infiltration of
CCR2-expressing monocytes, which provide a cellular
target for RS-102895, has yet to be determined. We
therefore considered evaluating monocytes/macrophages
in peripheral nerve tissue specifically; however, the yield
obtained during isolation was suboptimal for reliable
characterisation. We therefore used peritoneal lavages as
a surrogate source of monocytes [9]. Importantly, we
confirmed that CCR2 receptor is indeed detectable in
both control and lipopolysaccharide (LPS)-stimulated
peritoneal cells using both Western blot and FACS ana-
lysis of Ly6C+ CCR2
+ cells (Additional file 1: Figure S4).
In light of our evidence that CCR2 receptor is detectable,
we measured peritoneal CCR2
+ monocytes (F4/80− cells) in
CX3CR1-deficient and heterozygous mice following two
cycles of VCR using FACS analysis. We observed that in
both genotypes, two cycles of VCR treatment significantly
increased F4/80−Ly6C+CCR2
+ cells relative to saline-
treated controls (Fig. 4e, f). Furthermore, the number of
F4/80−Ly6C+CCR2+ cells in VCR-treated CX3CR1-defi-
cient mice was significantly greater than that measured in
heterozygous controls, indicating that CX3CR1 deficiency
was associated with an increase of CCR2+ monocyte num-
bers in vivo. Critically, treatment with RS-102895 during
the second VCR cycle significantly reduced the number of
F4/80−Ly6C+CCR2
+ cells to a greater extent in CX3CR1-de-
ficient mice (Fig. 4e, f ). Taken together, this data is
suggestive of an interaction between CX3CR1 and CCR2
receptors in monocytes.
Knocking down CX3CR1 expression in a human monocyte
cell line results in an increase in CCL2/R2 expression via
p38 MAPK signalling
In order to investigate whether CX3CR1 regulates CCR2
expression in monocytes, we knocked down CX3CR1 ex-
pression using siRNA in the human monocyte THP-1 cell
line, which resulted in an approximately 80% reduction in
CX3CR1 expression (Additional file 1: Figure S5A). As
shown previously [26], we confirmed that downregulation
of the CX3CR1 receptor in monocytes is accompanied by
an increase in CCL2 expression (Fig. 5a). In addition, how-
ever, a significant increase in CCR2 expression was also
observed, with CX3CR1 siRNA-transfected THP-1 cells
expressing significantly higher levels of CCR2 relative to
those transfected with control siRNA (Fig. 5b, Additional
file 1: Figure S4B). Furthermore, when cells were pre-
treated with the p38 MAP kinase inhibitor, SB203580,
downregulation of CX3CR1 (which is unaffected by
SB203580 administration (Additional file 1: Figure S5C))
did not result in an increase in CCR2 expression (Fig. 5c).
When cells were pre-treated with the MAPK/ERK kinase
inhibitor, PD98059, however, CX3CR1 downregulation
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resulted in an increase in CCR2 expression (Fig. 5c). Taken
together, these data suggest that downregulation of
CX3CR1 in THP-1 cells in vitro results in upregulation of
CCR2 receptor via p38 MAP Kinase signalling.
Downregulation of CX3CR1 regulates proinflammatory
cytokine levels in vitro
In order to begin to identify a mechanism by which an
interaction between CX3CR1 and CCR2 in monocytes
could potentially result in mechanical allodynia, we then
went on to establish whether this interaction regulates
the release of pronociceptive mediators. Indeed, down-
regulation of CX3CR1 resulted in a significant increase
in the basal release of the proinflammatory cytokines
TNF-α and IL1β to the same extent as stimulation of
non-transfected THP-1 cells with 10 ng/ml CCL2
(Fig. 5d, e). Furthermore, release of TNF-α and IL1β, fol-
lowing stimulation with higher doses of CCL2 (50 and
100 ng/ml), was not significantly higher than those ob-
served following CX3CR1 receptor downregulation alone
(Fig. 5d, e).
In short, our THP-1 cell data demonstrates the pres-
ence of a novel interaction between CX3CR1 and CCR2
receptor expression, which is mediated by p38 MAP
kinase signalling. In addition, it demonstrates that
the CX3CR1-CCR2 interaction in vitro regulates the re-
lease of pronociceptive cytokines, thus providing a po-
tential means by which monocytes could communicate
a b
e f
c d
Fig. 4 CX3CR1 deficiency increases CCR2 expression in vivo. a Representative blot for CCL2 (15 kDa) in CX3CR1
+/GFP and CX3CR1
GFP/GFP sciatic nerves.
b Quantification of CCL2 band density normalised to α-tubulin (mean ± SEM, n = 3). Basal expression of CCL2 in sciatic nerve homogenates is
significantly higher in CX3CR1-deficient mice relative to saline-treated CX3CR1 heterozygous. VCR significantly increases CCL2 in both genotypes.
*p < 0.05, ***p < 0.005, one-way ANOVA, Tukey’s test. c Representative images of GFP (macrophages) and CCL2 (red) in sciatic nerve transverse
sections at day 11. Scale bar = 50 μm. d Quantification of the percentage of GFP+ profiles that are also CCL2+. Two cycles of VCR significantly
increases the percentage of GFP+/CCL2+ macrophages in both genotypes (mean ± SEM, n = 4 mice per group). ***p < 0.005, one-way ANOVA,
post hoc Tukey’s test. e Representative dot blots for peritoneal lavages. Numbers in the gates refer to percentage of positive cells. f Bar chart
representing number of F4/80−Ly6C+CCR2+ events (mean ± SEM, n = 3). *p < 0.05, **p < 0.01 and ***p < 0.005, one-way ANOVA, Tukey’s test
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with sensory neurons in the mediation of allodynia in
CX3CR1-deficient mice during the second VCR cycle.
Discussion
Chemotherapy-induced painful neuropathy (CIPN) is a
dose-limiting side effect that jeopardises the success of
cancer therapy [1]. The need for novel, more effective
pain therapies, which necessitates a deeper understanding
of the underlying mechanisms, is therefore profound. Dif-
ferent chemotherapeutic agents are likely to induce CIPN
via a range of mechanisms, and thus, future therapies are
likely to be most effective if they are tailored for specific
cancer treatments.
a b
c
ed
Fig. 5 Downregulation of CX3CR1 increases the expression of CCL2/R2 and proinflammatory cytokines TNFα and IL-1β. a Representative Western
blot and quantification for CCL2 (15 kDa) in control siRNA and CX3CR1 siRNA-transfected THP-1 cells (mean ± SEM, n = 3 cultures, three wells per
culture were pooled). Expression of CCL2 is significantly elevated in CX3CR1 siRNA-transfected THP-1 cells relative to controls. *p < 0.01, Student’s t
test. b Representative Western blot and quantification for CCR2 (42 kDa) in control and CX3CR1 siRNA-transfected THP-1 cells ± pre-treatment with
either SB203580 (p38 MAP Kinase inhibitor) or PD98059 (MEK inhibitor). c Quantification of CCR2 expression (pg/ml) using ELISA (mean ± SEM,
n = 3 cultures). Transfection of THP-1 cells with CX3CR1 siRNA with PD98059 pre-treatment results in a significant increase in CCR2 expression. This
is not observed following pre-treatment with SB203580. **p < 0.01 relative to control siRNA transfected. d, e TNFα (d) and IL1β (e) quantification
by ELISA of THP-1 culture medium following transfection with CX3CR1 siRNA or 3 h stimulation with recombinant CCL2 (10, 50 and 100 ng/ml).
CX3CR1 downregulation and all concentrations of CCL2 significantly increase TNFα and IL1β expression (mean ± SEM, n = 3 cultures). *p < 0.05
and**p < 0.01 relative to control, Student’s t test
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In this study, we elucidate a mechanism underlying
pain associated with vincristine (VCR) treatment and
present evidence to suggest that CCR2 receptor signal-
ling in monocytes infiltrating the sciatic nerve plays a
role in VCR-induced allodynia in CX3CR1-deficient mice
during the second cycle specifically. We begin to eluci-
date a novel interaction between CX3CR1 and CCR2 in
monocytes and demonstrate in vitro that it regulates the
release of proinflammatory cytokines that have been pre-
viously shown to modulate neuronal mechanisms under-
lying chronic pain [23, 29].
We initially show that in CCR2-deficient mice, VCR-
induced allodynia and concurrent monocyte infiltration
into the sciatic nerve develop to the same severity and
within the same time frame as CCR2 heterozygous litter-
mates but are both significantly reduced during the sec-
ond VCR cycle. Our findings from CCR2-deficient mice
however is not enough to confirm a role for CCR2 sig-
nalling in monocytes per se in VCR-induced pain. CCR2
mediates the egression of monocytes from the bone
marrow into the bloodstream where they survey the en-
vironment surrounding tissue [30, 31]. It is therefore
plausible that the reduction in allodynia that we observe
is a result of prevention of monocyte egression as op-
posed to CCR2 signalling in macrophages in the sciatic
nerve specifically. Indeed, pharmacological inhibition of
CCR2 affords a very different scenario biologically to
CCR2 deficiency and as such is accompanied by different
behavioural and biological manifestations. Specifically,
when we administered the CCR2 antagonist RS-102895
to VCR-treated mice during the second cycle, we ob-
served that neither VCR-induced allodynia nor mono-
cyte infiltration into the sciatic nerve was reduced.
Our pivotal observation however was that RS-102895
administration during the second VCR cycle did signifi-
cantly reduce established VCR-induced allodynia and
monocyte infiltration into the sciatic nerve of CX3CR1-
deficient mice. Indeed, in keeping with this, CCR2 recep-
tor inhibition in CX3CR1-deficient mice specifically has
also been found to be protective in other pathological
conditions such as macular degeneration [27].
In addition we found that the (i) VCR-induced increase
in CCR2
+ monocytes in the peritoneal cavity was exacer-
bated in CX3CR1-deficient mice and (ii) RS-102895 treat-
ment significantly reduced the VCR-induced increase in
CCR2+ monocytes in CX3CR1-deficient mice specifically.
Taken together, these data are suggestive of an interaction
between CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/
receptor systems in monocytes that could underlie the on-
set of VCR-induced allodynia in CX3CR1-deficient mice.
Interactions between CX3CR1 receptor and CCL2 have
been reported previously in other contexts. Indeed, in
addition to our observation that CCL2 is elevated in the
sciatic nerve of CX3CR1-deficient mice, the expression
of CCL2 has also been shown to be elevated in mono-
nuclear phagocytes in the retina in CX3CR1-deficient
mice [27]. Here, we present novel evidence that CCR2 re-
ceptor expression is also altered downstream of CX3CR1
downregulation in vitro. Specifically, when we downregu-
lated CX3CR1 expression in immortalised human mono-
cyte THP-1 cells, we observed a significant upregulation
in both CCL2 and CCR2. Pharmacological inhibition of
p38 MAPK but not MEK prevented this effect, and thus,
we suggest that downregulation of CX3CR1 results in up-
regulation of the CCR2 receptor via p38 MAPK signalling.
As well as CX3CR1-mediated regulation or CCL2 and
CCR2 expression in monocytes, the converse interaction
has also been observed previously. Specifically, CCL2
stimulation of monocytes has been found to increase
CX3CR1 receptor expression at monocyte membranes,
most likely due to the stimulation of receptor transloca-
tion from intracellular stores as opposed to the stimula-
tion of de novo expression [31]. This regulation has
been shown to occur via CCR2-mediated activation of
p38 MAPK, with pharmacological inhibition of p38
MAPK, attenuating the effect [31]. This data, in con-
junction with the data presented in our study, suggests
that the interaction between CX3CR1 and CCR2 recep-
tors in monocytes is reciprocal and that expression of
CX3CR1 and CCR2 is mutually regulated.
As well as CX3CR1 deficiency being associated with an
increase in CCL2-CCR2 expression, VCR treatment was
also found to increase CCL2. Elevated CCL2/CCR2 sig-
nalling in CX3CR1-deificient mice under basal conditions
could explain the efficacy of RS-102895. The basal eleva-
tion of CCL2/CCR2 signalling alone in CX3CR1-deficient
mice is not likely to be sufficient to cause allodynia as
withdrawal thresholds did not vary between saline-
treated CX3CR1-deficient and heterozygous mice. How-
ever, the potentially additive effect of CX3CR1 deficiency
and two cycles of VCR on CCL2/CCR2 expression could
indeed result in susceptibility to hypersensitivity. This
could account for the onset of allodynia in CX3CR1-defi-
cient mice at later stages of VCR treatment and the
therapeutic benefit of CCR2 inhibition, which could also
be attributed to increases in CCR2+ monocytes found in
CX3CR1-deficient mice. Indeed, CCL2/R2 signalling in
sensory neurons is a well-established mediator of pain.
The elevation of CCR2
+ monocytes and CCL2 expression
in sciatic nerves that we observe in CX3CR1-deficient
mice, in addition to VCR-induced increases in CCL2, is
likely to cumulatively increase activity of the CCL2/
CCR2 signalling axis in sensory neurons, thus activating
pain pathways [32–34].
Whereas CX3CR1 is mainly found in monocytes/mac-
rophages, the CCR2 receptor is expressed by other cell
types. Elucidating the role of CCR2 signalling in mono-
cytes/macrophages specifically is therefore a more
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intricate process than unravelling the role of CX3CR1 sig-
nalling in monocytes. For instance, the CCR2 receptor is
also expressed in sensory neurons [17]. To attribute at
least part of our observed effect of RS-102895 in CX3CR1-
deficient mice to inhibition of CCR2 in monocytes specif-
ically, we needed to consider a role for CCR2 inhibition in
sensory neurons. A well-established downstream target of
CCR2 signalling in neurons is p-ERK activation, which is
associated with noxious activation of sensory neurons
[25]. At the end of two cycles of VCR treatment, we
found that p-ERK2 is elevated in DRG neurons in both
CX3CR1-deficient and heterozygous mice. However,
RS-102895 reduced VCR-associated p-ERK2 expres-
sion to the same extent in both genotypes despite the
fact that allodynia is significantly reduced in CX3CR1-defi-
cient mice. Although this does not rule out a role for
CCR2-mediated neuronal activation in VCR allodynia,
since thresholds observed in CX3CR1-deficient mice are
still considered to be allodynic, it could suggest that other
CCR2-mediated mechanisms are just as pivotal in regulat-
ing the severity of allodynia. Another key observation was
that after the treatment was terminated, p-ERK2 activa-
tion in VCR-treated mice that also received RS-102895
was no longer reduced, regardless of the genotype. Cru-
cially, however, allodynia was still significantly reduced in
CX3CR1-deficient mice, despite measureable p-ERK2 acti-
vation. This could suggest one of two things: either the
reduction in VCR allodynia in RS-102895-treated
CX3CR1-deficient mice does not depend on the effect on
neuronal activation or the dominant underlying mecha-
nisms regulating VCR allodynia change as VCR pain
evolves into ongoing after VCR treatment is terminated.
Regardless of the explanation, however, our data suggests
that there is scope for CCR2-mediated mechanisms that
do not only require activation of CCR2 in sensory neurons
to regulate VCR-associated allodynia in CX3CR1-deficient
mice. CCR2 signalling in monocytes could be a candidate
for such a mechanism.
Indeed, our final, crucial observation was that downreg-
ulation of CX3CR1 in human monocytes in vitro regulated
basal release of the proinflammatory cytokines TNFα and
IL1β. It is well-established that both TNFα and IL1β are
pronociceptive [29, 35], and thus, this provides us with a
crucial link between the CX3CR1-CCR2 interaction in
monocytes and noxious signalling. Indeed, we con-
firmed that CCL2 stimulation of THP-1 cells also results
in TNFα and IL1β release and observed that both CCL2
and CCR2 are elevated in THP-1 cells when CX3CR1 is
downregulated thus suggesting that downregulation of
CX3CR1 results in the release of proinflammatory cyto-
kines through heightened CCL2/CCR2 signalling. Our data
suggests the presence of a novel interaction between
CX3CR1 and CCR2 receptors, which regulates the release
of monocyte-derived signals that mediate communication
between monocytes and nociceptive neurons (Fig. 6). Crit-
ically, in vivo, we observe that under basal conditions,
CX3CR1 deficiency is associated with an increase in CCL2
in macrophages in the sciatic nerve and that VCR treat-
ment increases CCL2 expression further, which would cu-
mulatively result in the release of pronociceptive cytokines
and thus mediate pain signalling.
Conclusions
Our data provides exciting evidence for a novel role of
CCR2 receptor signalling in monocytes in VCR-associated
allodynia in CX3CR1-deficient mice, which is likely to mani-
fest as a result of an interaction between CX3CR1 and CCR2
expression in monocytes in the periphery. Identification of
this interaction could thus uncover a new therapeutic
target for longer-term treatment of vincristine pain.
Fig. 6 CCL2/CCR2 signalling in monocytes/macrophages plays a crucial role in VCR pain in CX3CR1-deficient mice. (1) Downregulation or silencing
of CX3CR1 in monocytes results in upregulation of CCR2 via p38 MAP kinase signalling. (2) Monocytes infiltrate through the endothelium into
peripheral nerve tissue in a CCL2/CCR2-dependent manner. (3) Cytokines such as TNFα and IL1β are released downstream of CCR2 signalling in
monocytes. (4) TRPV1 channels mediate noxious signalling following TNFα receptor activation in sensory neurons
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Additional file
Additional file 1: Table S1. Antibodies used for immunohistochemistry.
Table S2. Antibodies used for Western blot analysis. Figure S1. No microglial
response is detectable in VCR-treated CCR2 heterozygous or knockout mice.
Figure S2. Prophylactic treatment of CX3CR1 heterozygous mice with
RS-102895 does not affect the onset or severity of allodynia in cycle 1.
Figure S3. Treatment with RS-102895 does not reduce VCR-associated
allodynia in CX3CR1
+/GFP mice. Figure S4. Peritoneal monocytes/macrophages
express CCR2 under basal conditions. Figure S5. Transfection of THP-1 cells
with CX3CR1 siRNA downregulates CX3CR1 expression and upregulates CCR2
expression via p39 MAP kinase. (DOCX 960 kb)
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